Harmonized diagnostic criteria for Alzheimer's disease: Recommendations

Journal of Internal Medicine

Volumn 275, Issue 3, 2014, Pages 204-213

  Morris, J C ^a   Blennow, K ^b   Froelich, L ^c   Nordberg, A ^d   Soininen, H ^e,f   Waldemar, G ^g   Wahlund, L O ^h   Dubois, B ^i,j  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

Alzheimer biomarkers; Alzheimer's disease; Clinical diagnostic criteria; Preclinical Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CARBON 11; FLORBETABEN; TAU PROTEIN;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; CEREBROSPINAL FLUID; COMPARATIVE EFFECTIVENESS; CONSENSUS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; EPISODIC MEMORY; HUMAN; INTERNATIONAL WORKING GROUP CRITERIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL HEALTH ORGANIZATION; NATIONAL HEALTH ORGANIZATION ALZHEIMERS ASSOCIATION CRITERIA; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENILE PLAQUE;

ALZHEIMER BIOMARKERS; ALZHEIMER'S DISEASE; CLINICAL DIAGNOSTIC CRITERIA; PRECLINICAL ALZHEIMER'S DISEASE;

ALGORITHMS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; NEUROIMAGING; PRODROMAL SYMPTOMS;

EID: 84895727628     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12199     Document Type: Article

References (50)

1. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-46.
2. Dubois B, Feldman H, Jacova C et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-27.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-44.
4. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92. PMCID: PMC3220946.
5. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9. PMCID: PMC3312027.
6. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging and the Alzheimer's association workgroup. Alzheimers Dement 2011; 7:263-9. PMCID: PMC3312024.
7. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011; 77:1-17. PMC3130546.
8. Clark CM, Xie S, Chittams J et al. CSF tau and β-amyloid: how well do these biomarkers reflect autopsy confirmed dementia diagnoses? Arch Neurol 2003; 60: 1696-702.
9. Tapiola T, Alafuzoff I, Herukka S-K et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382-9.
10. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
11. Clark CM, Schneider JA, Bedell BJ et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 2011; 305: 275-83.
12. Vandenberghe R, Van Laere K, Ivanoiu A et al. 18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment a phase 2 trial. Ann Neurol 2010; 68: 319-29.
13. Barthel H, Gertz HJ, Dresel S et al., Florbetaben Study Group. Cerebral amyloid-B PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10: 424-35.
14. Cselenyi Z, Jonhagen ME, Forsberg A et al. Clinical validation of 18F-AZD4694, and amyloid-B-specific PET radioligand. J Nucl Med 2012; 53: 415-24.
15. Ikonomovic MD, Klunk WE, Abrahamson EE et al. Post-mortem correlates of in-vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-45.
16. Dickerson BC, Bakkour A, Salat DH et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009; 19: 497-510.
17. Wang L, Brier MR, Snyder AZ et al. Cerebrospinal fluid AB42, phosphorylated tau181, and resting-state functional connectivity. JAMA Neurol 2013; 70: 1242-8.
18. Beason-Held LL, Goh JO, An Y et al. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci 2013; 33: 18008-14.
19. Jack CR Jr, Albert MS, Knopman DS et al. Introduction to the recommendations from the national institute on aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 257-62.
20. Frisoni GB, Galluzzi S, Signorini M et al. Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis; report of 2 cases. Alzheimer Dis Assoc Disord 2010; 24: 108-14.
21. Bouwman FH, Verwey NA, Klein M et al. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 2010; 30: 1-7.
22. Galluzzi S, Geroldi C, Ghidoni R et al., Translational Outpatient Memory Clinic Working Group. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 2010;257:2004-14.
23. Oksengard AR, Cavallin L, Axelsson R et al. Lack of accuracy for the proposed 'Dubois criteria' in Alzheimer's disease: a validation study from the Swedish brain power initiative. Dement Geriatr Cogn Disord 2010; 30: 374-80.
24. Jack CR, Knopman DS, Weigand SD et al. An operational approach to national institute on aging-Alzheimer's association criteria for preclinical Alzheimer disease. Ann Neurol 2012; 71: 765-75.
25. Knopman DS, Jack CR Jr, Wiste HJ et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurol 2012; 78: 1576-82.
26. Vos SJB, Xiong C, Visser PJ et al. Prevalence and outcome of preclinical Alzheimer's disease. Lancet Neurol 2013; 12: 957-65. NIHMS:MIHMSID 525894.
27. Roe CM, Fagan AM, Grant EA et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784-91.
28. Lim YY, Maruff P, Pietrzak RH et al., for the AIBL Research Group. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014; 137: 221-231.
29. National Research Council of the National Academies. Toward Precision Medicine; Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Committee on a Framework for Developing a New Taxonomy of Disease, Board of Life Sciences, Division on Earth and Life Studies, editors. 1-128. 2011. Washington, DC, The National Academies Press.
30. Bateman RJ, Xiong C, Benzinger TLS et al., for the Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804. PMCID: PMC3474597.
31. 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-9.
32. Morris JC, Roe CM, Grant EA et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer's disease. Arch Neurol 2009; 66: 1469-75. PMC2798814.
33. Griffith HR, Belue K, Sicola A et al. Impaired financial abilities in mild cognitive impairment. Neurology 2003; 60: 449-57.
34. Farias ST, Mungas D, Reed BR, Harvey D, Cahn-Weiner D, DeCarli C. MCI is associated with deficits in everyday functioning. Alzheimer Dis Assoc Disord 2006; 20: 217-23.
35. Peres K, Chrysostome V, Fabrigoule C, Orgogozo JM, Dartigues J-F, Barberger-Gateau P. Restriction in complex activities of daily living in MCI; impact on outcome. Neurology 2006; 67: 461-6.
36. Berg L, McKeel DW Jr, Miller JP et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998; 55: 326-35.
37. Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathological outcomes in original versus revised MCI and in PreMCI. Neurology 2006; 67: 467-73.
38. Chiu HFK, Brodaty H. Arguments against the biomarker-driven diagnosis of AD. Int Psychogeriatr 2013; 25: 177-81.
39. Draper B, Peisah C, Snowdon J, Brodaty H. Early dementia diagnosis and the risk of suicide and euthanasia. Alzheimers Dement 2010; 6: 75-92.
40. Rohde K, Peskind ER, Raskind MA. Suicide in two patients with Alzheimer's disease. J Am Geriatr Soc 1995; 43: 187-9.
41. Lim WS, Rubin EH, Coats M, Morris JC. Early stage Alzheimer disease represents increased suicidal risk in relation to later stages. Alzheimer Dis Assoc Disord 2005; 19: 214-9.
42. Erlangsen A, Zarit SH, Conwell Y. Hospital-diagnosed dementia and suicide: a longitudinal study using prospective, nationwide register data. Am J Geriatr Psychiatry 2008; 16: 220-8.
43. Carpenter BD, Xiong C, Porensky EK et al. Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment. J Am Geriatr Soc 2008; 56: 405-12.
44. Tarek ME, Segers K, Van Nechel C. What Belgian neurologists and neuropsychiatrists tell their patients with Alzheimer disease and why: a national survey. Alzheimer Dis Assoc Disord 2009; 23: 33-7.
45. Connell CM, Gallant MP. Spouse caregivers' attitudes toward obtaining a diagnosis of a dementing illness. J Am Geriatr Soc 1996; 44: 1003-9.
46. Lin KN, Liao YC, Wang PN, Liu HC. Family members favor disclosing the diagnosis of Alzheimer's disease. Int Psychogeriatr 2005; 17: 679-88.
47. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-4.
48. Morris JC, Selkoe DJ. Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. Neurobiol Aging 2011; 32: S1-3.
49. Alladi S, Xuereb J, Bak T et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130: 2636-45.
50. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 2012; 6: 455-76. NIHMS406854.